IXA
USPTO Trademark Record
PENDINGIXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
SN 77775341·Reg 0·Filed
Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.
IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY (Serial No. 77775341), Registration No. 0, is a pending US trademark by Bristol-Myers Squibb Company. This trademark covers Class 042 (Scientific, technology & SaaS services).
